immunotech documento stem cells 2009

17
1 Company Immunotech S. A. (IMT) is a private biotech company with headquarters in Buenos Aires, Argentina. It is focused on discovering and developing innovative pharmaceutical products to accelerate organ and tissue repair and to prevent infectious diseases. Currently, IMT efforts are based on proprietary molecules (synthetic oligonucleotides) with bio-regulatory properties. IMT staff members include biologists, biochemists, physicians, pharmacists and financial experts. They are highly motivated to aggressively drive IMT candidate products through clinical trials, in order to make them available to patients worldwide. IMT adheres to GCPs and maintains a high level of quality standards regarding data management. Technology IMT oligonucleotides (IMT ODNs) are approximately 24 nucleotides long and contain the sequence PyNTTTTGT, wherein Py is C or T and N is any deoxynucleotide, as the active portion of the molecule. IMT studies have demonstrated that these ODNs, mainly in their phosphorothioate version, can interact with certain human cells modifying their behaviour. Primary target cells of IMT ODNs include mesenchymal stem cells precursor cells (MSCPC), B lymphocytes, plasmacytoid dendritic cells and natural killer cells (NK cells). Upon interaction with IMT ODNs these cells can release cytokines and express cell surface proteins which orchestrate the response of the body to damage caused by foreign agents such as invading micro-organisms or trauma. In POC trials, IMT ODNs have been demonstrated to be useful in a wide field of medical applications especially as regenerative-agents in tissue repair medicine. IMT ODNs and Tissue Repair by Adult Stem Cells

Upload: ralest2

Post on 06-Apr-2018

219 views

Category:

Documents


0 download

TRANSCRIPT

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 1/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 2/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 3/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 4/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 5/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 6/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 7/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 8/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 9/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 10/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 11/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 12/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 13/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 14/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 15/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 16/17

8/3/2019 Immunotech Documento Stem Cells 2009

http://slidepdf.com/reader/full/immunotech-documento-stem-cells-2009 17/17